PEDRO HENRIQUE BRUEL TORRETTA

Índice h a partir de 2011
1
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • conferenceObject
    Rituximab treatment in antiAQP4 positive patients with a 6-month reinfusion protocol
    (2017) TORRETTA, P. H. B.; APOSTOLOS-PEREIRA, S. L.; PITOMBEIRA, M. S.; JORGE, F. M. H.; SATO, D. K.; CALLEGARO, D.
  • article 46 Citação(ões) na Scopus
    Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis
    (2019) OLIVEIRA, Luana Michelli; APOSTOLOS-PEREIRA, Samira Luisa; PITOMBEIRA, Milena Sales; TORRETTA, Pedro Henrique Bruel; CALLEGARO, Dagoberto; SATO, Douglas Kazutoshi
    Background: MOG-IgG-associated optic neuritis, encephalitis and myelitis (MONEM) is a recently recognized group of inflammatory central nervous system (CNS) disorders distinct from multiple sclerosis and neuromyelitis optica spectrum disorders. Limited data are available regarding the predictors of relapse in this condition. Objective: We aimed to evaluate the longitudinal serostatus of patients with MOG-IgG and to correlate serostatus with long-term clinical outcomes. Methods: Of 574 consecutive patients who presented with demyelinating inflammatory CNS disorders, we included 31 patients who were MOG-IgG-positive. Patients with MOG-IgG were followed up from 2011 to 2017 at the School of Medicine, University of SAo Paulo, Brazil. Results: Relapsing disease occurred in 23 out of 31 patients (74%), while 8 (26%) exhibited a monophasic course. All monophasic patients, as well as the majority of relapsing patients, became seronegative during clinical remission. Patients exhibiting disease activity in the last 2years were more likely to remain positive, with higher medium titres than those found in patients in clinical remission. Conclusion: MOG-IgG patients usually present with a relapsing course, and the risk of relapse was associated with longitudinally persistent MOG-IgG seropositivity. In contrast, patients who experienced a single attack became spontaneously seronegative for MOG-IgG during long-term follow-up.
  • conferenceObject
    Five-year follow-up of pediatric onset Neuromyelitis Optica Spectrum Disorders (NMOSD)
    (2017) PAOLILO, R. B.; PAZ, J. A.; APOSTOLOS-PEREIRA, S. L.; RIMKUS, C. D. M.; ARAUJO, A. L. P. C.; VENTURA, L. M. G. D. B.; PITOMBEIRA, M. S.; GOMES, A. B.; MATOS, A. D. M. B.; TORRETTA, P. H. B.; REED, U. C.; CALLEGARO, D.; SATO, D. K.
  • conferenceObject
    Case series: a specialty center 10 year experience with use of azathioprine in neuromielytis optica spectrum disorders (NMOSD)
    (2017) GOMES, A. B. A. G. R.; MATOS, A. de Moura Brasil; VENTURA, L. M. Gomes de Brito; PITOMBEIRA, M. Sales; PAOLILO, R. Barbosa; TORRETTA, P. H. Bruel; JORGE, F. Menucci de Haidar; SATO, D. Kazutoshi; CALLEGARO, D.; PEREIRA, S. L. Apostolos
  • conferenceObject
    Autoantibody profile (MOG-IgG-seropositive, AQP4-IgG-seropositive and seronegativity) as a visual outcome predictor after optic neuritis
    (2017) VENTURA, L. M. G. B.; PITOMBEIRA, M. S.; GOMES, A. B. A. G. R.; MATOS, A. M. B.; PAOLILO, R. B.; TORRETTA, P. H. B.; SOLLA, D. J. F.; SALLES, L. M. O. P.; MOURA, F. C.; SATO, D. K.; SAMIRA, P. L. A.; CALLEGARO, D.